Videos

Joshua Sabari, MD, NYU Langone Health discusses mortality among patients with EGFR-mutated advanced non-small cell lung cancer after starting first-line treatment with osimertinib.

Betty K. Hamilton, MD, Cleveland Clinic, Cleveland, Ohio, discusses the findings of a pilot trial analyzing patient-reported outcomes for the management of patients with acute graft-versus-host-disease.

At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Rebecca Heist, MD, discusses developments and advances in the treatment of small cell lung cancer.

At the Great Debates and Updates in Lung Cancer conference in Chicago, Illinois, Eddie Garon, MD, makes the case for immuno-oncology alone as the optimal course of treatment lung cancer with PD-L1 expression ≥50%.

At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Patrick Forde, MD, makes the case for chemotherapy plus immuno-oncology as the best treatment for patients with lung cancer who have a PD-L1 expression of ≥50%.

Vinai Gondi, MD, explains his position on prophylactic cranial irradiation for patients with small-cell lung cancer, a controversy he addressed in a debate session at the Great Debates and Updates in Lung Cancer conference in Chicago,...

Heather Wakelee, MD, discusses first-line treatment options for patients with EGFR-mutant non-small cell lung cancer.

At the 2023 Great Debates and Updates Conference in Chicago, IL, Helena Yu, MD, discusses the challenges of primary and secondary resistance to EGFR tyrosine kinase inhibitors among patients with lung cancer.

C. Ola Landgren, MD, PhD, participated in a debate on whether melphalan plus ASCT after induction therapy should continue to be the standard of care in frontline treatment of patients with multiple myeloma.